Company Profile
Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company develops, produces, and sells antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis.
Its portfolio also includes GR1801, an anti-rabies virus G protein bispecific antibody, GR1802, an anti-IL-4Ra monoclonal antibody, GR1603, a monoclonal antibody for systemic lupus erythematosus, GR2002 an anti-TSLP bispecific antibody, WM1R3, a family receptor bispecific antibody, GR2001, a monoclonal antibody, GR2201, a monoclonal antibody for VZV infection, GR1803, a bispecific antibody for multiple myeloma, GR1901, a bispecific antibody, WM202 a bispecific antibody, WM215, a single-domain antibody, GR1401, an anti-EGFR monoclonal antibody, and GR1405 an anti-PD-L1 monoclonal antibody. Founded in 2015, the company is based in Chongqing, China.